Publications

2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

CERTs Publications 2003

• Al-Khatib SA, Allen LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-2127.
• Al-Khatib SM, Allen LaPointe NM, Curtis LH, Kramer JM, Swann J, Honig P, Califf RM. Outpatient prescribing of antiarrhythmic drugs from 1995 through 2000. Am J Cardiol 2003;91:91-94.
• Allen LaPointe NM, Chen A, Hammill B, DeLong E, Kramer JM, Califf RM. Evaluation of the dofetilide risk-management program. Am Heart J 2003;146:894-901.
• Allen LaPointe NM, Pamer CA, Kramer JM. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. Pharmacotherapy 2003;23:1316-1321.
• Allen LaPointe NM, Al-Khatib SM, Kramer JM, Califf RM. Knowledge deficits related to the QT interval could affect patient safety. Ann Noninvasive Electrocardiol 2003;8:157-160.
• Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-2057.
• Brown SA, Ontjes DA, Lester GE, Lark RK, Hensler MB, Blackwood AD, Caminiti MJ, Backlund DC, Aris RM. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. Osteoporos Int 2003;14:442-449.
• Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003;62:1033-1037.
• Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2003;12:183-194.
• Chan Ka, Truman A, Gurwitz J, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003;163:728-734.
• Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-141.
• Everett WW, Coffin SE, Zaoutis T, Halpern SD, Strom BL. Smallpox vaccination: a national survey of emergency health care providers. Acad Emerg Med. 2003;10:606-611.
• Finkelstein JA, Stille C, Nordin J, Davis R, Raebel MA, Roblin D, Go AS, Smith D, Johnson CC, Kleinman K, Chan KA, Platt R. Reduction in antibiotic use among US children, 1996-2000. Pediatrics 2003;112:620-627.
• Finkelstein JA, Huang SS, Daniel J, Rifas-Shiman SL, Kleinman K, Goldmann D, Pelton SI, DeMaria A, Platt R. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics 2003;112:862-869.
• Hagen EA, Lautenbach E, Olthoff K, Blumberg EA. Low prevalence of colonization with vancomycin-resistant enterococcus in patients awaiting liver transplantation. Am J Transplant 2003;3:902-905.
• Hennessy S, Bilker WB, Zhou L, Weber AL, Brensinger C, Wang Y, Strom BL. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003;290:1494-1499.
• Hennessy S, Bilker WB, Weber A, Strom BL. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003;12:103-111.
• Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
• Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003;163:601-605.
• Lautenbach E, Larosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003;36:440-446.
• Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003;139:467-471.
• Liu X, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, Ebert SN. In vivo androgen treatment shortens the QT interval and increases the destinies of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 2003;57:28-36.
• Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-118.
• Metlay JP, Strom BL, Asch DA. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. J Antimicrob Chemother 2003;51:963-970.
• Metlay JP, Hardy C, Strom BL. Agreement between patient self-report and a Veterans Affairs national pharmacy database for identifying recent exposures to antibiotics. Pharmacoepidemiol Drug Saf 2003;12:9-15.
• M'ikanatha NM, Southwell B, Lautenbach E. Automated laboratory reporting of infectious diseases in a climate of bioterrorism. Emerg Infect Dis 2003;9:1053-1057.
• M'ikanatha NM, Lautenbach E, Kunselman AR, Julian KG, Southwell BG, Allswede M, Rankin JT, Aber RC. Sources of bioterrorism information among emergency physicians during the 2001 anthrax outbreak. Biosecur Bioterror 2003;1:259-265.
• Mikuls TR, Mudano AS, Pulley L, Saag KG. Association of race/ethnicity with the receipt of traditional and alternative arthritis-specific health care. Med Care 2003;41:1233-1239.
• Mudano AS, Casebeer L, Patino F, Allison JJ, Weissman NW, Kiefe CI, Person S, Gilbert D, Saag KG. Racial disparities in osteoporosis prevention in a managed care population. South Med J 2003;96:445-451.
• Patino FG, Olivieri J, Allison JJ, Mikuls TR, Moreland L, Kovac SH, Juarez L, Person S, Saag KG. Nonsterioidal antiinflammatory drug toxicity monitoring and safety practices. J Rheumatol 2003;30:2680-2688.
• Patino FG, Allison J, Olivieri J, Mudano A, Juarez L, Person S, Mikuls TR, Moreland L, Kovac SH, Saag KG. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. Arthritis Rheum 2003;49:293-299.
• Pearson S-A, Ross-Degnan D, Payson A, Soumerai SB. Changing medication use in managed care: a critical review of the available evidence. Am J Manag Care 2003;9:715-731.
• Peterson ED, Kaul P, Kaczmarek RG, Hammill BG, Armstrong PW, Bridges CR, Ferguson TB Jr; Society of Thoracic Surgeons. From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes. J Am Coll Cardiol 2003;42:1611-1616.
• Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920.
• Ray WA, Daugherty JR, Meador KG. Effect of a mental health "carve-out" program on the continuity of antipsychotic therapy. N Engl J Med 2003;348:1885-1894.
• Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003;32:135-157.
• Stiles RA, So SA. Impact of transaction costs on healthcare outcomes. Expert Review of Pharmacoeconomis & Outcomes Research 2003;3:283-291.
• Strom BL. Risk assessment of drugs, biologics and therapeutic devices: present and future issues. Pharmacoepidemiol Drug Saf 2003;12:653-662.
• Walson PD, Cox S, Utkin I, Gerber N, Crim L, Brady M, Koranyi K. Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults. Ther Drug Monit 2003;25:650-656.